DiaMedica Therapeutics price target raised to $10 from $7 at H.C. Wainwright

H.C. Wainwright analyst Matthew Caufield raised the firm’s price target on DiaMedica Therapeutics (DMAC) to $10 from $7 and keeps a Buy rating on the shares. The firm believes the greatest near-term catalyst for the recombinant human tissue kallikrein-1 vascular disease pipeline is the preliminary Phase 2 investigator-sponsored safety and efficacy topline anticipated in Q2 for pregnancy complication preeclampsia. The firm is optimistic going into the dataset for DiaMedica’s lead candidate DM199.